– Leading-edge Senella® soft tissue technology awarded for excellence in B2B / medical technologies
BellaSeno GmbH, an ISO 13485-certified medtech company developing absorbable scaffolds using additive manufacturing technologies, today announced that the Company has received the German Innovation Award from the German Design Council for its Senella® technology in the category #W2 Excellence in Business to Business – Medical Technologies. BellaSeno has been chosen among about 700 applicants from 30 countries, covering both bluechip as well as innovative start-up companies.
Senella® has been designed to alleviate the complications and risks found in current breast reconstruction and augmentation approaches. Based on a patented porous scaffold made of an absorbable biocompatible polymer that is FDA-approved and CE-marked for a variety of clinical applications and used routinely in the clinic for over 30 years, Senella® is absorbed over a span of two years. The clinical end result is a natural soft tissue – without remnants of foreign material.
Senella® is currently being developed for breast reconstruction and the rare chest defect pectus excavatum. First-in-human trials are ongoing.
“We are delighted to receive the German Innovation Award in the category medical technologies,” said Mohit Chhaya, PhD, Co-founder and CEO of BellaSeno. “The award is an important recognition of our work in the field of natural tissue reconstruction. Our goal is to provide patients and surgeons with safer, more natural alternatives to standard breast reconstruction approaches, ultimately leading to a restoration of the natural breast.”
The German Innovation Award recognizes enterprises with an impact. It honours the added value created by small details or new solutions. The prize was presented for the first time in 2018. It is aimed at small businesses as well as corporate groups – both B2B and B2C – i.e. at all companies with innovative products that are part of an overall solution. The German Design Council was founded in 1953 by the German Bundestag and is funded by the Federation of German Industries.
BellaSeno GmbH was founded in 2015 and is located on the BioCity campus in Leipzig, Germany. The Company is developing novel absorbable soft tissue reconstruction implants made by additive manufacturing (3D-printing) under ISO 13485 certification. The Company has received substantial financial support from private investors as well as from the Saxony Development Bank (SAB), the European Fund for Regional Development (EFRE) and Germany´s Federal Ministry of Education and Research (BMBF). The Company is thereby co-funded from tax resources based on the budget adopted by the members of Saxon State Parliament.
Senella® is a patented porous scaffold made of absorbable Polycaprolactone (PCL) containing highly-specialized topological and design features, which act as recipients for injected fat tissue isolated with a standard liposuction procedure. The implant is designed to get absorbed over a span of two years and to provide a stable platform for the injected fat tissue to mature, adapt to its environment and stabilize. The clinical end result is a natural soft tissue – without remnants of foreign material. Senella® therefore has the potential to alleviate the complications found in current breast reconstruction and augmentation approaches.